Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Keywords/Phrases:  PD 0332991
Results 1-25 of 322 for your search:
Start Over
PD 0332991 in Treating Patients With Refractory Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 03909, NCI-2009-01467, NCT01037790
PD-0332991 in Treating Patients With Recurrent Ovarian Epithelial, Fallopian tube, or Primary Peritoneal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-003234, NCI-2012-00287, NCT01536743
PD-0332991, Fluorouracil, and Oxaliplatin in Treating Patients With Refractory Metastatic Colorectal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2011-219, NCI-2013-00658, NCT01522989
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201301106, NCI-2012-02202, NCT01723774
PD-0332991 and Paclitaxel in Treating Patients With Metastatic Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 02111, NCI-2011-00414, NCT01320592
Palbociclib Isethionate in Treating Younger Patients with Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: PBTC-042, NCI-2014-00640, NCT02255461
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: GBG78/BIG 1-13/NSABP-B-54-I, NCI-2014-02553, 2013-001040-62, NCT01864746
Palbociclib in Treating Patients with Metastatic Urothelial Cancer after First-Line Chemotherapy Failure
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1406, NCI-2015-00532, 14-2196, WI187190, NCT02334527
Palbociclib and Cetuximab in Treating Patients with Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201404139, NCI-2014-01079, 14-X031, NCT02101034
Ibrutinib and Palbociclib Isethionate in Treating Patients with Previously Treated Mantle Cell Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1403014853, NCI-2014-01202, 9534, NCT02159755
Palbociclib Isethionate and Ado-Trastuzumab Emtansine in Treating Patients with Recurrent or Metastatic HER2-Positive Breast Cancer
Phase: Phase I
Type: Treatment
Age: 18 to 90
Trial IDs: SCCC-05113, NCI-2014-00821, 042013-042, Mod9_STU 042013-042, NCT01976169
Palbociclib Isethionate and PD0325901 in Treating Patients with Non-small Cell Lung Cancer or Other Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-506, NCI-2014-00940, NCT02022982
Palbociclib Isethionate and Endocrine Therapy in Treating Patients with Hormone Receptor-Positive Stage II-III Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-559, NCI-2014-00937, NCT02040857
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 200344, NCI-2014-01119, NCT02065063
Androgen Deprivation Therapy with or without Palbociclib Isethionate in Treating Patients with RB-Positive Metastatic Hormone-Sensitive Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2013.117, NCI-2014-01922, HUM00082715, NCT02059213
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400, NCI-2014-00627, S1400A, S1400B, S1400C, S1400D, S1400E, NCT02154490
Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA209-040, NCI-2013-00864, 2012-001514-42, NCT01658878
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA224-020, NCI-2014-00315, 2014-002605-38, NCT01968109
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: R2810-ONC-1423, NCI-2015-00512, NCT02383212
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)
Phase: Phase II, Phase I
Type: Treatment
Age: 6 months to less than 18 years
Trial IDs: 3475-051, NCI-2015-00528, 2014-002950-38, NCT02332668
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 and over
Trial IDs: MCC-15651, NCI-2011-00737, CDR0000682183, NCI-P8316, P-8316, 8316, NCT01176474
A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B1641003, NCI-2014-01800, KEYNOTE-0036, NCT02179918
Start Over